The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a significant price target suggests a strong positive outlook for ArriVent BioPharma. This endorsement is likely to attract investor attention and could lead to a short-term increase in the stock price, reflecting the analyst's confidence in the company's future performance.